{"id":"W4389246769","doi":"10.1182/blood-2023-182128","title":"Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; CancerCare Manitoba; Jewish General Hospital","funders":"Genentech; Swedish Orphan Biovitrum; Astellas Pharma; Incyte; BeiGene; Regeneron Pharmaceuticals; Adaptive Biotechnologies; Karyopharm Therapeutics; Gilead Sciences; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Takeda Oncology; Amgen","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Refractory (planetary science); Cohort; Phases of clinical research; Chemotherapy regimen; Cancer; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004286317,0.0005634304,0.001698421,0.0006327186,0.0002025128,0.001225642,0.0006549438,0.0006398101,0.001375426],"category_scores_gemma":[0.002140235,0.0003972926,0.002033857,0.0007018981,0.000318227,0.0008388754,0.0002727508,0.001199288,0.000287424],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001033578,"about_ca_system_score_gemma":0.001073433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008066288,"about_ca_topic_score_gemma":0.003296288,"domain_scores_codex":[0.9987545,0.0006201853,0.000110028,0.000192975,0.0002082875,0.0001140918],"domain_scores_gemma":[0.9982265,0.0004523518,0.0006813258,0.0001314491,0.0002417181,0.0002666381],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3711652,0.00771742,0.1224392,0.004573494,0.020014,0.0005132287,0.0005041463,0.003298194,0.04563443,0.0003960897,0.00867765,0.415067],"study_design_scores_gemma":[0.2663302,0.208094,0.4432008,0.000964194,0.02560125,0.002566196,0.0002279315,0.003127922,0.009746843,0.0006833303,0.0392799,0.0001774438],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9564052,0.03447419,0.0008329857,0.0007480435,0.0001432411,0.001337795,0.003285779,0.000107716,0.002665051],"genre_scores_gemma":[0.9815338,0.009261752,0.001649395,0.001164608,0.0001973742,0.0006859967,0.00467199,0.00003026046,0.0008048027],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004286317,"threshold_uncertainty_score":0.02266848,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02560226847192373,"score_gpt":0.3162612581474971,"score_spread":0.2906589896755734,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}